What is RAPT Therapeutics Inc (RAPT) stock price today?

RAPT Therapeutics Inc (RAPT) currently trades at $58.02 per share. The stock has a market capitalization of $1.68B and a P/E ratio of —x.

Is RAPT stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, RAPT Therapeutics Inc has a Smart Value Score of 21/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -2.26.

Is RAPT Therapeutics Inc financially healthy?

RAPT Therapeutics Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -2.26 places it in the distress.

RAPT

RAPT Therapeutics Inc

NASDAQ: RAPT · HEALTHCARE · BIOTECHNOLOGY

$58.02

+0.00% today

Updated 2026-03-04

Market cap

$1.68B

P/E ratio

—

P/S ratio

411.22x

EPS (TTM)

$-11.66

Dividend yield

—

52W range

$6 – $58

Volume

3.2M

Market cap

$1.68B

P/E ratio

—

P/S ratio

411.22x

EPS (TTM)

$-11.66

Dividend yield

—

52W range

$6 – $58

Volume

3.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-2.3

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$58.00

-0.03%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy0 Buy9 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.02x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -2.26 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-12.46M

- Revenue declining -1.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2021	2022	2023	2024	TTM
Revenue	$3.81M	$1.53M	$0.00	$0.00	$0.00
Net income	$-68.21M	$-81.88M	$-116.80M	$-129.87M	$-17.58M
EPS	—	—	—	—	$-11.66
Free cash flow	$-61.78M	$-71.62M	$-98.17M	$-83.42M	$-12.46M
Profit margin	-1,788.83%	-5,362.21%	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
RAPT	$1.68B	21	3.7	3.0	5.0	6.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

RAPT Therapeutics Inc trades at $58.02. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -2.26, it sits in the distress.

Frequently asked questions

What is RAPT Therapeutics Inc's stock price?

RAPT Therapeutics Inc (RAPT) trades at $58.02.

Is RAPT Therapeutics Inc overvalued?

Smart Value Score 21/100 (Grade F, Strong Sell).

What is the price target of RAPT Therapeutics Inc (RAPT)?

The analyst target price is $58.00, representing -0.0% downside from the current price of $58.02.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-2.26 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.rapt.com

Quick metrics

P/S ratio411.22x

ROE-0.85%

Beta0.44

50D MA$49.94

200D MA$27.42

Shares out0.03B

Float0.02B

Short ratio—

Avg volume3.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

RAPT vs LLY →RAPT vs JNJ →RAPT vs ABBV →Stock screener →